Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

KalVista Pharmaceuticals (KALV) Shares Outstanding (Weighted Average): 2014-2025

Historic Shares Outstanding (Weighted Average) for KalVista Pharmaceuticals (KALV) over the last 7 years, with Apr 2025 value amounting to $49.7 million.

  • KalVista Pharmaceuticals' Shares Outstanding (Weighted Average) rose 17.84% to $49.7 million in Q2 2025 from the same period last year, while for Oct 2024 it was $49.4 million, marking a year-over-year increase of 43.64%. This contributed to the annual value of $49.7 million for FY2025, which is 17.84% up from last year.
  • KalVista Pharmaceuticals' Shares Outstanding (Weighted Average) amounted to $49.7 million in Q2 2025, which was up 0.60% from $49.4 million recorded in Q4 2024.
  • In the past 5 years, KalVista Pharmaceuticals' Shares Outstanding (Weighted Average) registered a high of $49.7 million during Q2 2025, and its lowest value of $17.9 million during Q1 2021.
  • In the last 3 years, KalVista Pharmaceuticals' Shares Outstanding (Weighted Average) had a median value of $42.5 million in 2024 and averaged $42.1 million.
  • Data for KalVista Pharmaceuticals' Shares Outstanding (Weighted Average) shows a peak YoY spiked of 43.64% (in 2024) over the last 5 years.
  • KalVista Pharmaceuticals' Shares Outstanding (Weighted Average) (Quarterly) stood at $17.9 million in 2021, then reached $34.4 million in 2023, then spiked by 43.64% to $49.4 million in 2024, then climbed by 17.84% to $49.7 million in 2025.
  • Its Shares Outstanding (Weighted Average) was $49.7 million in Q2 2025, compared to $49.4 million in Q4 2024 and $49.4 million in Q4 2024.